Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunovant, Inc.IMVT · Entity 3632 | Director | May 01, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunovant, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,394 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Sale · Disposed 2,502 · Balance 36,394 F1: The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 1, 2026 22:40 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 2,502 | $27.17 | $67,979.34 |
DisclosureSEC source: 0001764013-26-000058 · wk-form4_1777675214.xml · nonDerivative · entry 1 Susman Robert Graham · CIK 0002065992 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,394 F1 · shares: The transaction reported on this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 - $27.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 7,061 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000042 · wk-form4_1775766147.xml · derivative · entry 2 Susman Robert Graham · CIK 0002065992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,061 Underlying: Common Stock · 7,061 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:22 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 13,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000042 · wk-form4_1775766147.xml · nonDerivative · entry 1 Susman Robert Graham · CIK 0002065992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,896 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:30 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (Right to Buy) · Derivative | 35,234 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001415889-25-012045 · form4-05052025_070501.xml · derivative · entry 2 Susman Robert Graham · CIK 0002065992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,234 Underlying: Common Stock · 35,234 shares Expires 2035-05-01 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:30 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 25,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012045 · form4-05052025_070501.xml · nonDerivative · entry 1 Susman Robert Graham · CIK 0002065992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,016 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in three equal annual installments beginning on May 1, 2025, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.